Abstract: Ingenol angelate is a potent anticancer agent, and can be stabilised by dissolving it in an aprotic solvent in the presence of an acidic buffer.

Abstract: Compositions for topical administration of a hedgehog inhibitor compound are described. In one embodiment, the hedgehog inhibitor compound is patidegib and the topical composition comprises the compound in a solvent system of a monohydric primary alcohol and a polyol in a w/w ratio of between about 0.9-1.8. In another embodiment, the hedgehog inhibitor is itraconazole and the topical composition comprises the compound in a solvent system comprising a monohydric primary alcohol and an optionally lower alkyl end-capped oligomeric alkylene glycol in a w/w ratio of between about 0.8 and 2.6 and a fused bicyclic ether. Method of using the compositions are also described, where in one embodiment, the compositions are topically applied for treating or preventing basal cell carcinoma.

Abstract: Ingenol angelate is a potent anticancer agent, and can be stabilised by dissolving it in an aprotic solvent in the presence of an acidic buffer.

Abstract: Ingenol angelate is a potent anticancer agent, and can be stabilised by dissolving it in an aprotic solvent in the presence of an acidic buffer.

Abstract: Ingenol angelate is a potent anticancer agent, and can be stabilised by dissolving it in an aprotic solvent in the presence of an acidic buffer.

Abstract: Ingenol angelate is a potent anticancer agent, and can be stabilised by dissolving it in an aprotic solvent in the presence of an acidic buffer.

Abstract: A method of travel analytics can include: detecting a signal of a first mobile computing device (MCD) at a first location with a first signal tracker; obtaining real time travel data about the first MCD from the signal received by the first signal tracker; accessing a database having historical travel data for the first MCD; and comparing the historical travel data with the real time travel data for the first MCD to determine travel data for the first MCD. The method can include determining a mode of travel of the first MCD based on the travel data for the first MCD. The method can include predicting a travel route for the first MCD; and predicting a time of travel for the first MCD on the predicted travel route to a second signal tracker. The method can include providing a targeted advertisement on the travel route based on the travel data.

Abstract: A signal tracker can include: a housing; at least two signal detectors in the housing; a computing component in the housing and operably coupled with the at least two signal detectors so as to obtain signal data therefrom; a memory device in the housing communicatively coupled with the computing component so as to receive the signal data and store the signal data thereon; and a transmitter in the housing communicatively coupled with the computing component so as to be capable of transmitting the signal data to a network. The signal tracker can include one or more of the listed components. The housing can be a weatherproof housing. The signal tracker can include the at least two signal detectors being selected from the group consisting of a cellular detector, a Wi-Fi detector, or a Bluetooth detector.

Abstract: Unnatural, hygroscopic amino acids are useful to enhance the moisture retention and uptake properties of skin. In particular, such amino acids are N-hydroxyserine, N-hydroxyglycine, L-homoserine, alpha-hydroxyglycine, 2-(aminooxy)-2-hydroxyacetic acid, 2-hydroxy-2-(hydroxyamino) acetic acid, 2-(aininooxy)acetic acid, and combinations thereof.

Abstract: Embodiments are directed to a stable composition comprising stabilized hydrogen peroxide and 2-propanol and applicators configured to store, dispense, and apply such stable compositions. Such compositions may be used to treat skin conditions such as warts, condyloma accuminatum, molluscum contagiosum, acrochordons, seborrheic keratosis, or a combination thereof. Some embodiments also describe take home compositions, in office compositions, over-the-counter compositions, and kits for the use of such compositions.

Abstract: Mixtures of C1-12 compounds comprising at least one -Alk-O— group with thermogenic formulations, such as those comprising supercooled solutions of salts, are capable of substantial enhancement of transdermal drug delivery.

Abstract: Ingenol angelate is a potent anticancer agent, and can be stabilised by dissolving it in an aprotic solvent in the presence of an acidic buffer.

Abstract: Ingenol angelate is a potent anticancer agent, and can be stabilized by dissolving it in an aprotic solvent in the presence of an acidic buffer.

Abstract: Ingenol angelate is a potent anticancer agent, and can be stabilized by dissolving it in an aprotic solvent in the presence of an acidic buffer.

Abstract: Ingenol angelate is a potent anticancer agent, and can be stabilized by dissolving it in an aprotic solvent in the presence of an acidic buffer.

Abstract: Embodiments relating to gels comprising imidazoline alpha agonists, such as, without limitation, oxymetazoline or a pharmaceutically acceptable salt thereof, and methods for treating diseases, such as, without limitation, rosacea, including, for example, erythematotelangiectatic rosacea, papulopustular rosacea, phymatous rosacea, ocular rosacea or combinations thereof; and symptoms associated with rosacea, including, for example, papules, pustules, phymas (skin thickening), telangiectasias or erythema or redness associated with rosacea, other skin erythemas, telangiectasias, purpura or the like, and other manifestations associated therewith or combinations thereof using such gels are described herein.

Abstract: Ingenol angelate is a potent anticancer agent, and can be stabilized by dissolving it in an aprotic solvent in the presence of an acidic buffer.

Abstract: Ingenol angelate is a potent anticancer agent, and can be stabilized by dissolving it in an aprotic solvent in the presence of an acidic buffer.